Ticagrelor Tablets 90 Mg

Ticagrelor Tablets 90 Mg – Advanced Antiplatelet Therapy for Heart Protection

Ticagrelor Tablets 90 Mg is a prescription cardiovascular medication used to reduce the risk of major thrombotic (blood clot) events in adults with acute coronary syndrome (ACS) or a history of myocardial infarction (heart attack). It belongs to a class of medicines known as antiplatelet agents. These medicines help prevent platelets — the blood components responsible for clotting — from clumping together, which can block arteries and cause serious cardiovascular events.

Cardiovascular disease is a leading cause of death worldwide. After events like heart attack or stent placement, antiplatelet therapy plays a crucial role in reducing the risk of recurrence and serious complications like heart attack and stroke. Ticagrelor is often prescribed as part of dual antiplatelet therapy (DAPT) in appropriate patients for improved protection.

How Ticagrelor Tablets 90 Mg Work

Ticagrelor Tablets 90 Mg work by preventing platelet aggregation in the bloodstream:

1. Blocks P2Y12 Receptors

Ticagrelor directly and reversibly inhibits the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP)–induced activation.

2. Reduces Clot Formation

By blocking platelet activation, ticagrelor decreases the chance of blood clots forming in arteries, which can lead to heart attack or stroke.

3. Rapid Onset of Action

Ticagrelor has a quicker onset of action compared with some older antiplatelet agents, making it effective soon after dosing in medically appropriate patients.

4. Improved Secondary Prevention

Clinical studies demonstrate reduced rates of cardiovascular death and recurrent events in eligible patients compared with some alternative agents.

Indications

Ticagrelor Tablets 90 Mg may be prescribed for:

• Reducing risk of thrombotic cardiovascular events in adults with acute coronary syndrome (ACS)

• Secondary prevention after myocardial infarction

• In selected patients, as part of dual antiplatelet therapy (DAPT)

This medication should only be used under professional medical supervision with appropriate clinical evaluation.

Sustained-release metabolic cardiac care models may include Trimetazidine SR Tablets 60 Mg within long-term cardiovascular management.

Dosage & Administration

• Typically taken twice daily

• Swallow with water at consistent times daily

• May be taken with or without food

• Follow your healthcare provider’s prescribed instructions

• Do not stop or alter the dose without medical advice

Consistent and correct use is key to achieving the intended cardioprotective benefits.

Chronic angina management frameworks may integrate Trimetazidine HCl Tablets 20 Mg as part of supervised cardiovascular therapy.

Safety Information & Precautions

Before starting Ticagrelor Tablets 90 Mg, inform your healthcare provider if you have:

• Active bleeding or bleeding disorders

• Recent surgery or risk of bleeding

• History of stroke or intracranial hemorrhage

• Severe liver impairment

• Conditions that increase bleeding risk

Asthma treatment strategies are based on evidence-based clinical data published by leading public health authorities like the CDC.

Important Safety Notes

• Bleeding risk is increased with antiplatelet drugs — monitor for unusual bleeding

• Notify all care providers that you are taking ticagrelor

• Inform your clinician if you are pregnant or planning to become pregnant

Possible Side Effects

Common side effects may include:

• Shortness of breath (dyspnea)

• Headache

• Dizziness

• Nosebleeds

• Nausea

Seek immediate medical care if you experience severe bleeding, unusual bruising, black/tarry stools, or signs of allergic reaction.

Drug Interactions

Ticagrelor may interact with:

• Other antiplatelet or anticoagulant medications

• NSAIDs (e.g., ibuprofen)

• Certain antibiotics and antifungals

• CYP3A4 inhibitors and inducers

Always inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are taking.

Use in Special Populations

Pregnancy

Consult a healthcare provider before use.

Breastfeeding

Speak with your clinician before taking this medication.

Elderly Patients

May need closer monitoring due to higher bleeding risk in older adults.

Monitoring & Follow-Up

Patients taking Ticagrelor Tablets 90 Mg should have:

• Regular clinical follow-up

• Monitoring for any sign of bleeding

• Cardiovascular risk assessment

• Possible periodic blood work

Ongoing care ensures optimal safety and therapeutic effect.

FAQs